The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration

•A tulobuterol patch containing a β2-adrenergic agonist at two different doses was investigated.•The pharmacokinetics of tulobuterol was evaluated in dogs after intravenous and transdermal administration.•A therapeutic blood concentration was reached with both transdermal doses.•The tulobuterol patc...

Full description

Saved in:
Bibliographic Details
Published in:The veterinary journal (1997) Vol. 208; pp. 90 - 92
Main Authors: Kim, J.H., Kim, T.H., Park, H.J., Choi, Y.J., Kang, J.H., Song, K.H., Koo, T.S., Seo, K.W.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-02-2016
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A tulobuterol patch containing a β2-adrenergic agonist at two different doses was investigated.•The pharmacokinetics of tulobuterol was evaluated in dogs after intravenous and transdermal administration.•A therapeutic blood concentration was reached with both transdermal doses.•The tulobuterol patch can be safely and effectively used in dogs. Tulobuterol is a β2-adrenergic agonist that was the first bronchodilator approved as a transdermal patch for humans. Previous studies have examined the pharmacokinetics of tulobuterol in humans but not in the veterinary species. In this study, the pharmacokinetics of tulobuterol was examined in healthy Beagle dogs after transdermal and intravenous administration. The Cmax was 2.09 ng/mL at 16.0 h for a 0.2 mg/kg patch and 4.85 ng/mL at 13.6 h for a 0.4 mg/kg patch. The effective blood level in humans is 1–3 ng/mL, a concentration achieved using the 0.2 mg/kg patch in dogs. In conclusion, application of a 0.2 mg/kg tulobuterol patch to healthy dogs led to an apparently effective blood concentration for 24 h.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1090-0233
1532-2971
DOI:10.1016/j.tvjl.2015.10.012